CITATION REPORT List of articles citing

Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells

DOI: 10.2119/2006-00083.kallergi Molecular Medicine, 2007, 13, 79-88.

Source: https://exaly.com/paper-pdf/42510959/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
72	Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells. <i>Cellular Physiology and Biochemistry</i> , 2007 , 20, 977-86	3.9	78
71	Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells. <i>Experimental Cell Research</i> , 2008 , 314, 3162-74	4.2	54
70	Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2008 , 10, R80	8.3	103
69	Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 7050-9	12.9	66
68	Micrometastatic disease in breast cancer: clinical implications. European Journal of Cancer, 2008, 44, 27	2 6. §6	25
67	Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008 , 139, 237-44	2.4	34
66	Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. <i>Pathobiology</i> , 2008 , 75, 140-8	3.6	93
65	Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. <i>Journal of Clinical Pathology</i> , 2008 , 61, 570-6	3.9	49
64	Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 2593-600	12.9	197
63	Circulating tumor cells in breast cancer. Current Opinion in Obstetrics and Gynecology, 2008, 20, 55-60	2.4	21
62	Claudin-7 regulates EpCAM-mediated functions in tumor progression. <i>Molecular Cancer Research</i> , 2009 , 7, 285-99	6.6	93
61	ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. <i>Experimental Cell Research</i> , 2009 , 315, 707-16	4.2	44
60	Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2009 , 11, R84	8.3	93
59	Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells. <i>Cell Biology International</i> , 2010 , 34, 815-26	4.5	14
58	Ethanol enhances the interaction of breast cancer cells over-expressing ErbB2 with fibronectin. <i>Alcoholism: Clinical and Experimental Research</i> , 2010 , 34, 751-60	3.7	24
57	Prolactina novel neuroendocrine regulator of human keratin expression in situ. <i>FASEB Journal</i> , 2010 , 24, 1768-79	0.9	53
56	Circulating cancer cells. <i>Annals of Oncology</i> , 2010 , 21 Suppl 7, vii95-100	10.3	39

55	Circulating tumor cells. <i>Progress in Molecular Biology and Translational Science</i> , 2010 , 95, 95-112	4	32
54	Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. <i>Cancer Letters</i> , 2010 , 289, 127-39	9.9	207
53	Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis. <i>Future Oncology</i> , 2010 , 6, 209-19	3.6	13
52	Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2011 , 13, R59	8.3	271
51	Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. <i>Breast Cancer Research</i> , 2011 , 13, R60	8.3	66
50	Detection of circulating tumor cells: Clinical relevance of a novel metastatic tumor marker. <i>Experimental and Therapeutic Medicine</i> , 2011 , 2, 385-391	2.1	9
49	Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 723-32	4.9	7
48	Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 1151-73	4.9	138
47	Focal adhesion kinase-regulated signaling events in human cancer. <i>Biomolecular Concepts</i> , 2012 , 3, 225	-49 7	9
46	The p85lregulatory subunit of PI3K mediates cAMP-PKA and retinoic acid biological effects on MCF7 cell growth and migration. <i>International Journal of Oncology</i> , 2012 , 40, 1627-35	4.4	12
45	Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. <i>Cancer and Metastasis Reviews</i> , 2012 , 31, 663-71	9.6	65
44	Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. <i>Breast Cancer Research</i> , 2012 , 14, R15	8.3	234
43	Proteomic research progress in lymphatic metastases of cancers. <i>Clinical and Translational Oncology</i> , 2012 , 14, 21-30	3.6	17
42	Dormant but migratory tumour cells in desmoplastic stroma of invasive ductal carcinomas. <i>Clinical and Experimental Metastasis</i> , 2012 , 29, 273-92	4.7	16
41	Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. <i>Molecular Oncology</i> , 2013 , 7, 680-92	7.9	69
40	Apoptotic circulating tumor cells in early and metastatic breast cancer patients. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1886-95	6.1	77
39	Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. <i>Breast Cancer Research</i> , 2014 , 16, 485	8.3	42
38	Periostin induces intracellular cross-talk between kinases and hyaluronan in atrioventricular valvulogenesis. <i>Journal of Biological Chemistry</i> , 2014 , 289, 8545-61	5.4	43

37	Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. <i>BMC Cancer</i> , 2014 , 14, 651	4.8	75
36	Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers. <i>Carcinogenesis</i> , 2014 , 35, 2074-83	4.6	51
35	The role of FAK in tumor metabolism and therapy. <i>Pharmacology & Therapeutics</i> , 2014 , 142, 154-63	13.9	63
34	Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2015 , 17, 113	8.3	21
33	Androgens Regulate T47D Cells Motility and Invasion through Actin Cytoskeleton Remodeling. <i>Frontiers in Endocrinology</i> , 2016 , 7, 136	5.7	15
32	The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells. <i>Breast Cancer Research</i> , 2016 , 18, 37	8.3	15
31	Circulating Tumor Cells. Advances in Experimental Medicine and Biology, 2016, 882, 235-58	3.6	43
30	Novel Biomarkers in the Continuum of Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016 ,	3.6	9
29	Prognostic Implications of CTC in Breast Cancer. Current Cancer Research, 2016, 233-254	0.2	
28	Circulating Tumor Cells. Current Cancer Research, 2016,	0.2	4
28	Circulating Tumor Cells. <i>Current Cancer Research</i> , 2016 , Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib. <i>Lung Cancer</i> , 2017 , 104, 16-23	5.9	20
	Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer		
27	Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib. <i>Lung Cancer</i> , 2017 , 104, 16-23 TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).	5.9	20
27 26	Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib. <i>Lung Cancer</i> , 2017 , 104, 16-23 TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC). <i>Scientific Reports</i> , 2017 , 7, 45351 Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small	5.9 4.9	20
27 26 25	Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib. <i>Lung Cancer</i> , 2017 , 104, 16-23 TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC). <i>Scientific Reports</i> , 2017 , 7, 45351 Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. <i>PLoS ONE</i> , 2017 , 12, e0181211 Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.	5.9 4.9 3.7 3.3	20 16 21
27 26 25	Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib. <i>Lung Cancer</i> , 2017 , 104, 16-23 TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC). <i>Scientific Reports</i> , 2017 , 7, 45351 Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. <i>PLoS ONE</i> , 2017 , 12, e0181211 Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. <i>Oncotarget</i> , 2017 , 8, 5309-5322 Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients	5.9 4.9 3.7 3.3	20 16 21 24
27 26 25 24 23	Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib. <i>Lung Cancer</i> , 2017 , 104, 16-23 TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC). <i>Scientific Reports</i> , 2017 , 7, 45351 Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. <i>PLoS ONE</i> , 2017 , 12, e0181211 Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. <i>Oncotarget</i> , 2017 , 8, 5309-5322 Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib. <i>Scientific Reports</i> , 2018 , 8, 2238 Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by	5·9 4·9 3·7 3·3	20 16 21 24 11

19	Tumor Liquid Biopsies. Recent Results in Cancer Research, 2020,	1.5	5
18	Integrin IIB in the Mediating Effects of Dihydrotestosterone and Resveratrol on Breast Cancer Cell Proliferation. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	10
17	The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?. <i>Prostate Cancer</i> , 2020 , 2020, 7938280	1.9	3
16	Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 21, 1037-1048	3.8	2
15	Breast. 2010 , 347-376		27
14	Clinical Applications of Circulating Tumor Cells in Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020 , 215, 147-160	1.5	4
13	Circulating tumor cells in germ cell tumors: are those biomarkers of real prognostic value? A review. <i>Medicine and Pharmacy Reports</i> , 2016 , 89, 203-11	1.5	4
12	TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer. <i>Oncotarget</i> , 2015 , 6, 12392-404	3.3	25
11	pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2016 , 7, 2646-59	3.3	35
10	Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. <i>Oncotarget</i> , 2016 , 7, 41677-41690	3.3	30
9	Detection and Characterization of Disseminated Tumor Cells present in Bone Marrow of Cancer Patients. 2010 , 103-117		
8	Circulating Tumor Cells in Breast Cancer. 2010 , 219-234		
7	Breast. 2010 , 419-460		
6	Adhesion Molecule Phosphorylation in Cancer Chemotherapy. 2010 , 341-358		
5	PARP-1 Expression and Mutations in Breast Cancer PatientsUCTCs Cancers, 2022, 14,	6.6	O
4	Transcription phenotype of circulating tumor cells in non-metastatic breast cancer <i>Carcinogenesis</i> , 2021 ,	4.6	
3	Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate. 2022 , 14, 3903		2
2	Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer. 2023 , 13,		1

Immune Checkpoint and EMT-Related Molecules in Circulating Tumor Cells (CTCs) from Triple Negative Breast Cancer Patients and Their Clinical Impact. **2023**, 15, 1974

О